Our Team

Brian Sullivan

Brian has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously he was co-founder and CEO of Recovery Engineering, a filtration company that he took public and subsequently sold to Proctor and Gamble for $265 million in 1999. He has received nine U.S. patents. He graduated magna cum laude with distinction from Harvard College with an A.B. degree in economics.

Lance Laing, PhD

Lance’s career spans more than 20 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from Johns Hopkins University and completed a National Institutes of Health postdoctoral fellowship at Washington University Medical School. He has received 22 U.S. patents. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased by Novartis), where he worked under Professor Peter Kim, the recently retired president of Merck Research Laboratories. Most recently, Lance served as an executive director for an international drug discovery and development company.

Lance has built a world-class science team that includes drug discovery, cell signaling, high-throughput drug screening, molecular oncology and human primary cell culture scientists.

Vicky Hahne

Vicky has more than 20 years of financial leadership experience, including the past 10 years in the healthcare industry. Prior to joining Celcuity, Vicky served as Controller of Respiratory Technologies Inc., a medical device manufacturer. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke Philips. Prior to Respiratory Technologies, she served as Controller for Ability Network Inc., a healthcare information technology company. From September 2007 through June 2012, Vicky served as Controller of Sterilmed Inc., a medical device reprocessing company, where she played a key role in the sale of the company to Johnson & Johnson. Prior to these roles, Vicky held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer. Vicky has extensive experience in early stage, high growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions, building infrastructure, and systems. She received a Bachelor of Science degree in Finance and Accounting from Northern State University and received her CPA certificate in 1990.

Igor Gorbatchevsky, MD

Igor has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Prior to joining Celcuity, Igor worked for MEI Pharma (MEI), an oncology focused biopharmaceutical company, where he was the VP of Clinical Development. MEI’s pipeline included zandelisib, an oral PI3K-delta inhibitor. He had previously served as the VP of Clinical Science at Iovance Biotherapeutics, as a Global Clinical Leader at Bayer Pharmaceuticals, and as a Senior Medical Director at Daiichi-Sankyo a global pharmaceutical company. At Bayer, his responsibilities included leadership of the Global Clinical Development Team for ALIQOPA (copanlisib), a pan-PI3K inhibitor approved by the FDA for treatment of patients with follicular lymphoma. Prior to joining industry, he was a practicing clinician treating a broad range of tumor types in adults and children. Igor received his medical training at Omsk State Medical Academy with specialty training in clinical immunology at Chelyabinsk State Medical Academy.

Eldon Mayer

Eldon has over 30 years of biopharma commercial experience in companies ranging from early-stage biotech’s to full scale pharmaceutical companies across many therapeutic areas, including oncology.  Prior to joining Celcuity, Eldon was Chief Commercial Officer at Eiger Biopharmaceuticals where he led the commercial planning and execution of several pipeline assets including the global launch of Zokinvy® for progeria and progeroid laminopathies.  Before Eiger, Eldon was Chief Commercial Officer at Rigel Pharmaceuticals where he built the commercial organization from the ground up and successfully launched Tavalisse® for chronic immune thrombocytopenia.  Eldon had previously served as Senior Vice President of Commercial Operations at Questcor Pharmaceuticals where he built a large commercial team that generated over $1 billion in annual sales of Acthar®.  Earlier in his career, Eldon held positions of increasing responsibility at companies such as Schering-Plough, ALZA, Chiron, and Connetics in strategic planning, marketing, sales, market research/analytics, and finance.  Eldon has served as a member of the board of directors for Eiger BioPharmaceuticals, Promet Therapeutics, and the National Community Oncology Dispensing Association.  Eldon holds a BS degree from Fairleigh Dickinson University and an MBA from Syracuse University.

Brent Eilefson

Brent has over 29 years of legal experience, including 20 years in the pharmaceutical industry. Prior to joining Celcuity, Brent was Vice President, Legal Affairs, Chief Compliance Officer, and Secretary at Upsher-Smith Laboratories, where he held positions of increasing responsibility within management including leading the legal, compliance, and corporate secretarial functions. As a member of the senior management team at Upsher-Smith, Brent managed all legal activities to support the R&D, clinical, regulatory, manufacturing, marketing, and sales teams. His experience also included in- and out-licensing transactions, acquisitions and divestitures, and managing complex litigation related to antitrust, commercial disputes, and products liability. Brent’s legal experience outside of the pharmaceutical industry includes private law firm practice advising clients in regulated industries and trial/appellate practice. Brent holds a BA in History and Philosophy from St. Olaf College and a JD from Mitchell Hamline School of Law.

Bernhard Lampert, PhD

Bernhard has over 30 years of drug development experience in the pharmaceutical and biotech industries, including 10 years in large, fully integrated pharmaceutical companies, including Gilead and GSK. He received his PhD in Medicinal Chemistry from the University of Georgia in 1989. Bernhard has authored/co-authored publications in peer-reviewed journals and is the co-inventor on patents on the manufacture of antiviral drugs.

Nadene Zack

Nadene has over 20 years of experience working in clinical operations for clinical-stage pharmaceutical and biotechnology companies. She has broad experience in therapeutic areas (oncology, psychiatry, rheumatology & pain, pulmonology, infectious disease, and women’s health). Before joining Celcuity, Nadene held positions of increasing responsibility at Pfizer, Cypress Bioscience, Aragon Pharmaceuticals, and Daré Bioscience, leading to NDA submissions and approvals for milnacipran (Savella®) and apalutimide (ERLEADA®), and XACIATO™, respectively.

Nadene holds a Bachelor of Science Degree in Health Science from San Diego State University and a Master of Science in Clinical Research Administration from George Washington University.

Sunni Miller

Sunni Miller has over 20 years of experience in the pharmaceutical industry, building and directing regulatory teams and managing various therapeutic development programs and health authority submissions and interactions through all stages of development. Before joining Celcuity, Sunni served as VP, Regulatory Affairs and Clinical Quality Assurance at Gossamer Bio and as Senior Director, Global Regulatory Affairs at Ignyta. Her previous experience also included regulatory affairs positions at Gilead Sciences and Teva Pharmaceutical. Sunni received her Bachelors of Arts degree in Chemistry from Michigan State University.

David Bridge

David has over 30 years of experience as a quality assurance leader, including quality oversight responsibilities for laboratory, manufacturing, and clinical functions.  Prior to joining Celcuity, David was Director of Quality Assurance at the Duke University Clinical Research Institute, one of world’s largest academic clinical research organizations.  He had previously served as Senior Director, Quality Assurance for Chimerix, a biopharmaceutical company developing antiviral therapies, and Clinical Quality Assurance Leader at EMD Pharmaceuticals, the US affiliate for Merck KGaA.

William Strickland, PharmD

Bill has over 20 years of experience in the pharmaceutical industry with demonstrated Medical Affairs leadership and new drug launch experience. Before joining Celcuity, Bill was the Vice President of Medical Affairs at Elevar Therapeutics, where he led development of the medical affairs function and its launch readiness plan. Prior to his experience at Elevar, he held leadership roles of increasing responsibility at Allergen, AstraZeneca, Bristol-Myers Squibb, and GSK. Bill received his Doctor of Pharmacy (PharmD) from the University of Michigan.

Fred Kerwood

Fred has over 30 years of program management and clinical operations experience in the pharmaceutical industry.  Before joining Celcuity, Fred was VP of Clinical Operations at CytomX Therapeutics where he oversaw the execution of their oncology programs, including a Phase 2 program in breast cancer.  Prior to CytomX, Fred was with the immuno-oncology company Immune Design, a subsidiary of Merck, where he was the VP of Project Management and Clinical Operations. Fred also spent 10 years at Johnson & Johnson, where he served in various program management, new product development and strategic marketing roles. He has an MBA in science and technology from LaSalle University and a Bachelor of Science degree in psychology / biochemistry from Texas A&M University.

Charlotte Moser, MD, PhD

Charlotte has over 25 years of experience as a clinician, researcher, and drug developer. Prior to joining Celcuity, Charlotte served as the Chief Medical Officer of Deka Biosciences. She had previously served as Chief Science Officer of Nanocan Therapeutics and Head of Clinical Development of Galera Therapeutics. Prior to joining industry, she was an academic clinical oncologist, serving as a Professor of Radiation Oncology at the University of Lisbon and Professor of Clinical Oncology at the Brest University Hospital Center in France. She received her medical training at Vrije University, her PhD in Biostatistics at the University of Leiden, and her MBA from the MIT Sloan School of Management.

John R. MacDonald, PhD

John has over 30 years of experience in all aspects of pharmaceutical drug development and licensing. He led the preclinical and clinical R&D efforts at MGI Pharma, an oncology-focused company, from 1996 through 2005, and served as a consultant through MGI’s acquisition by Eisai in 2008. Prior to MGI he worked in large pharma at Warner-Lambert (now Pfizer) and in academia as an NIH funded researcher at UC San Francisco. Since 2006 he has remained active in drug development as a consultant advising academic institutions, startup and small pharma companies as the founder of Ridge Road Consulting and as the acting CEO of PepTx, Inc., a University of Minnesota startup. Dr. MacDonald earned a PhD in Pharmacology and Toxicology from the University of Arizona.